358 related articles for article (PubMed ID: 18802703)
1. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M; Mihara M
Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
3. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
4. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
6. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
7. Altered interleukin-6 receptor, IL-6R and gp130, production and expression and decreased SOCS-3 expression in placentas from women with pre-eclampsia.
Zhao S; Gu Y; Dong Q; Fan R; Wang Y
Placenta; 2008 Dec; 29(12):1024-8. PubMed ID: 18986700
[TBL] [Abstract][Full Text] [Related]
8. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
[TBL] [Abstract][Full Text] [Related]
9. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
10. Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130.
Yasukawa K; Futatsugi K; Saito T; Yawata H; Narazaki M; Suzuki H; Taga T; Kishimoto T
Immunol Lett; 1992 Feb; 31(2):123-30. PubMed ID: 1740350
[TBL] [Abstract][Full Text] [Related]
11. IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.
Lee SY; Buhimschi IA; Dulay AT; Ali UA; Zhao G; Abdel-Razeq SS; Bahtiyar MO; Thung SF; Funai EF; Buhimschi CS
J Immunol; 2011 Mar; 186(5):3226-36. PubMed ID: 21282511
[TBL] [Abstract][Full Text] [Related]
12. Soluble gp130 is up-regulated in the implantation window and shows altered secretion in patients with primary unexplained infertility.
Sherwin JR; Smith SK; Wilson A; Sharkey AM
J Clin Endocrinol Metab; 2002 Aug; 87(8):3953-60. PubMed ID: 12161539
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
14. Age-related increased prevalence of asthma and nasal polyps in chronic rhinosinusitis and its association with altered IL-6 trans-signaling.
Cho SH; Kim DW; Lee SH; Kolliputi N; Hong SJ; Suh L; Norton J; Hulse KE; Seshadri S; Conley DB; Kern RC; Tan BK; Peters A; Grammer LC; Schleimer RP
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):601-6. PubMed ID: 26266960
[TBL] [Abstract][Full Text] [Related]
15. A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing.
Wolf J; Waetzig GH; Reinheimer TM; Scheller J; Rose-John S; Garbers C
Biochem Biophys Res Commun; 2016 Feb; 470(4):870-6. PubMed ID: 26809098
[TBL] [Abstract][Full Text] [Related]
16. Role of interleukin-6, its receptor and soluble gp130 in chronic lung disease of prematurity.
Chakraborty M; McGreal EP; Davies PL; Nowell MA; Jones S; Kotecha S
Neonatology; 2013; 104(3):161-7. PubMed ID: 23921508
[TBL] [Abstract][Full Text] [Related]
17. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.
Narazaki M; Yasukawa K; Saito T; Ohsugi Y; Fukui H; Koishihara Y; Yancopoulos GD; Taga T; Kishimoto T
Blood; 1993 Aug; 82(4):1120-6. PubMed ID: 8353278
[TBL] [Abstract][Full Text] [Related]
18. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
[TBL] [Abstract][Full Text] [Related]
19. Role of interleukin-15 and interleukin-18 in the secretion of sIL-6R and sgp130 by human neutrophils.
Jablonska E; Marcinczyk M
Mediators Inflamm; 2003 Jun; 12(3):179-83. PubMed ID: 12857602
[TBL] [Abstract][Full Text] [Related]
20. Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19.
Rodríguez-Hernández MÁ; Carneros D; Núñez-Núñez M; Coca R; Baena R; López-Ruiz GM; Cano-Serrano ME; Martínez-Tellería A; Fuentes-López A; Praena-Fernandez JM; Garbers C; Hernández-Quero J; García F; Rose-John S; Bustos M
Front Immunol; 2022; 13():891456. PubMed ID: 35634332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]